[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565487":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":18,"responsibleParty":34,"collaborators":18,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":38,"sex":44,"minAge":45,"maxAge":18,"enrollmentInfo":46,"targetDuration":18,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":59,"whyStopped":18,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":18},{"fullName":5,"class":6},"University Hospital, Bordeaux","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group","EXPERIMENTAL","During the inclusion visit, urine collection jars will be given to the patient for collection at inclusion and at 3 months. Within the week after the inclusion visit: urine collection will be performed twice a day during 3 days at the patient's home and will be stored in the refrigerator at the participants' home. In the week following this collection, the PREVENIR platforms will be used. At three months, the clinical research officer will contact the patient to remind her of the need to collect urine twice a day during 3 days. This urine collection will be carried out with the same organization as at inclusion. Then, after this urine collection, all the participating women will be interviewed, with a questionnaire identical to the one used for the face-to-face inclusion, in order to allow for the measurement of exhaled Carbon Monoxide (CO). Within 3 to 5 months after inclusion, participating women of the intervention group only,will be invited to participate to the qualitative study.",[13],"Other: protocolized interview and prevention messages",{"label":15,"type":16,"description":17,"interventionNames":18},"Non-intervention group","NO_INTERVENTION","During the inclusion visit, urine collection jars will be given to the patient for collection at inclusion and at 3 months. Within the week after the inclusion visit: urine collection will be performed twice a day during 3 days at the patient's home and will be stored in the refrigerator at the participants' home. At three months, the clinical research officer will contact the patient to remind her of the need to collect urine twice a day during 3 days. This urine collection will be carried out with the same organization as at inclusion. Then, after this urine collection, all the participating women will be interviewed, with a questionnaire identical to the one used for the face-to-face inclusion, in order to allow for the measurement of exhaled CO. In the non-intervention group, the full intervention will take place at this time. The control group is a waiting list type control group. The procedure will be performed at the end of the study, i.e. three months after inclusion.",null,[20],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":18},"protocolized interview and prevention messages","This care consists of a consultation carried out by an environmental health expert (midwife, environmental health engineer) from the PREVENIR platforms. This consultation is carried out through a protocolized interview already developed which allows the identification of exposure to risk factors on reproduction. During the interview, prevention messages targeted at the exposures identified during the interview are delivered.",[9],[25],{"name":26,"affiliation":5,"role":27},"Fleur DELVA, MD","PRINCIPAL_INVESTIGATOR",[29],{"name":26,"role":30,"phone":31,"phoneExt":32,"email":33},"CONTACT","0557821684","33","fleur.delva@chu-bordeaux.fr",{"type":35,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100565487","evaluation-of-the-effectiveness-of-prevenir-prevention-environnement-reproduction-platforms-100565487",false,"NCT06642818","Evaluation of the Effectiveness of PREVENIR (PREVention ENvIronnement Reproduction) Platforms","Evaluation of the Effectiveness of PREVENIR (PREVention ENvIronnement Reproduction) Platforms on Urinary Markers of Chemical Exposures - Unblinded Randomized Clinical Trial. PREVENIR-G","PREVENIR-G","Inclusion Criteria:\n\n* All pregnant women less than 24 SA of age referred to the PREVENIR platforms participating in the study for management.\n* Only women less than 24 SA months pregnant will be included to limit the number of women who gave birth during the study.\n* More than 18 years old\n\nFor qualitative study:\n\n* Professionnal working within PREVENIR platforms\n* Women included in the intervention group and who agreed with participating\n\nExclusion Criteria:\n\n* Women under court protection, under guardianship or curatorship, severely altered physical and\u002For psychological health, which, in the opinion of the investigator, may affect the participant's compliance to the study.\n* Women with an altered medical condition related to prgnancy that may required a therapeutic abortion according to the environmental expert\n* Non-French speakers","ALL","18 Years",{"count":47,"type":48},300,"ESTIMATED","INTERVENTIONAL",[51],"NA","Unblinded randomized clinical superiority trial in two parallel groups (intervention vs. no intervention) national multicentre to evaluate the effectiveness of the platforms on the evolution of phenoxyacetic acid levels measured in the urine at inclusion and 3 months after the intervention for patients who received the intervention compared to patients who did not receive the intervention.",[54,55,56],"Pregnancy","Environmental Exposure","Prevention",[54,58,56],"Environmental exposure","NOT_YET_RECRUITING","2025-07-21",{"date":62,"type":63},"2025-07-25","ACTUAL",{"date":65,"type":48},"2025-09-01",{"date":67,"type":48},"2027-02-01",{"name":5,"class":6}]